KERX Keryx Biopharmaceuticals, Inc. (delisted)

Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease, today announced that corporate presentations would be delivered at the following upcoming investor conferences.

Morgan Stanley Global Healthcare Conference Presenter: Greg Madison, Chief Executive Officer Presentation Date: Thursday, September 17, 2015 Presentation Time: 2:05 p.m. ET

Ladenburg Thalmann 2015 Healthcare Conference Presenter: Scott Holmes, Chief Financial Officer Presentation Date: Tuesday, September 29, 2015 Presentation Time: 1:00 p.m. ET

Live audio webcasts of these presentations will be accessible from Keryx's website at http://investors.keryx.com within the Investor Relations section under the "webcasts and presentations" page. Archived versions of the webcasts will be available following the conclusion of the live presentations.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals, with offices in New York and Boston, is focused on bringing innovative therapies to market for patients with renal disease. In December 2014, the Company launched its first FDA-approved product, Auryxia™ (ferric citrate) for the treatment of elevated serum phosphorus levels in patients with chronic kidney disease on dialysis, in the United States. In January 2014, ferric citrate was approved for the treatment of patients with all stages of CKD in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In July 2015, the CHMP of the European Medicines Agency recommended granting a market authorization for Fexeric® (ferric citrate coordination complex) for the treatment of hyperphosphatemia in adults with chronic kidney disease. For more information about Keryx, please visit www.keryx.com.

CONTACT: KERYX CONTACT:
         Lora Pike
         Senior Director, Investor Relations
         T: 617-466-3511
         lora.pike@keryx.com